A. Boezio

发表

Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.

D. Whittington, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.

K. Rex, K. Shah, Douglas Hoffman, 2008, Journal of medicinal chemistry.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.

Stephanie D. Geuns-Meyer, N. Gavva, Y. Teffera, 2016, Journal of medicinal chemistry.

1,2,4-Triazolsulfone: A novel isosteric replacement of acylsulfonamides in the context of NaV1.7 inhibition.

Kristin L. Andrews, R. Fremeau, M. Chu-Moyer, 2018, Bioorganic & medicinal chemistry letters.

Synthesis and activity of substituted carbamates as potentiators of the alpha4beta2 nicotinic acetylcholine receptor.

A. Malmberg, K. Clarkin, S. McDonough, 2008, Bioorganic & medicinal chemistry letters.

Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.

T. Bush, A. Cheng, D. Whittington, 2011, Bioorganic & medicinal chemistry letters.

The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement.

R. Fremeau, H. Bregman, M. Chu-Moyer, 2017, Bioorganic & medicinal chemistry letters.

Chemical reactivity of methoxy 4-o-aryl quinolines: identification of glutathione displacement products in vitro and in vivo.

B. Albrecht, J. Harmange, Y. Teffera, 2008, Chemical research in toxicology.

Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators.

A. Malmberg, K. Clarkin, S. McDonough, 2008, Bioorganic & medicinal chemistry letters.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

R. Fremeau, H. Bregman, M. Chu-Moyer, 2017, Journal of Medicinal Chemistry.

Asymmetric, catalytic synthesis of alpha-chiral amines using a novel bis(phosphine) monoxide chiral ligand.

A. Côté, A. Boezio, A. Charette, 2003, Journal of the American Chemical Society.

New methods in asymmetric catalysis based on new hemi-labile bidentate ligands

A. Côté, A. Boezio, V. Lindsay, 2008 .

Evidence for the structure of the enantioactive ligand in the phosphine-copper-catalyzed addition of diorganozinc reagents to imines.

A. Côté, A. Boezio, A. Charette, 2004, Angewandte Chemie.

Preparation of Enantiomerically Enriched (1S)‐1‐Phenylpropan‐1‐Amine Hydrochloride by a Catalytic Addition of Diorganozinc Reagents to Imines

A. Côté, A. Boezio, A. Charette, 2006 .

Catalytic asymmetric addition of diorganozinc reagents to N-phosphinoylalkylimines.

A. Côté, A. Boezio, A. Charette, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Tetraarylphosphonium salts as solubility-control groups: phosphonium-supported triphenylphosphine and azodicarboxylate reagents.

A. Boezio, A. Charette, Jean-Christophe Poupon, 2006, Angewandte Chemie.

Efficient total syntheses of (-)-colombiasin A and (-)-elisapterosin B: application of the Cr-catalyzed asymmetric quinone Diels-Alder reaction.

E. Jacobsen, A. Boezio, E. R. Jarvo, 2005, Angewandte Chemie.

Catalytic Enantioselective Addition of Dialkylzinc to N-Diphenylphosphinoylimines. A Practical Synthesis of α-Chiral Amines

A. Boezio, A. Charette, 2003 .

Mitsunobu reaction using triphenylphosphine linked to non-cross-linked polystyrene.

A. Boezio, A. Charette, M. K. Janes, 2001, The Journal of organic chemistry.

Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain

A. Malmberg, K. Clarkin, T. Juan, 2010, PAIN®.

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Roman Shimanovich, Angel Guzman-Perez, R. Fremeau, 2017, Journal of medicinal chemistry.

Direct, Regioselective N-Alkylation of 1,3-Azoles.

A. Boezio, R. Graceffa, Shuai Chen, 2016, Organic letters.

Development of novel azabenzofuran TRPA1 antagonists as in vivo tools.

Stephanie D. Geuns-Meyer, N. Gavva, A. Boezio, 2014, Bioorganic & medicinal chemistry letters.

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

K. Rex, A. Coxon, D. Whittington, 2016, Journal of medicinal chemistry.

Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2015, Journal of medicinal chemistry.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2012, Bioorganic & Medicinal Chemistry Letters.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

T. Bush, A. Cheng, P. Andrews, 2012, Bioorganic & medicinal chemistry letters.

8.06 – Discovery of AMG 337: Using Structure Guided Scaffold Hybridization to Optimize Physicochemical Properties and Target Coverage of a MET Kinase Inhibitor

J. Harmange, A. Boezio, E. A. Peterson, 2017 .

Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain

A. Malmberg, K. Clarkin, T. Juan, 2010, PAIN®.

Discovery of Pyridyl Urea Sulfonamide Inhibitors of NaV1.7.

B. Moyer, R. Shimanovich, A. Boezio, 2022, Bioorganic & medicinal chemistry letters.

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Shahein H. Tajmir, A. Schram, A. Frost, 2023, Cancer discovery.